BerandaFGEN • NASDAQ
add
FibroGen Inc
Tutup sebelumnya
$11,04
Rentang hari
$10,64 - $11,17
Rentang tahun
$4,50 - $21,94
Kapitalisasi pasar
45,19 jt USD
Volume Rata-Rata
32,08 rb
Rasio P/E
-
Hasil dividen
-
Bursa utama
NASDAQ
Berita pasar
Times Colonist
18 jam yang lalu
S&P/TSX finishes more than 280 points higher, U.S. stock markets mixed
0,43%
Keuangan
Laporan Pendapatan
Pendapatan
Laba bersih
| (USD) | Jun 2025info | Perubahan Y/Y |
|---|---|---|
Pendapatan | 1,35 jt | 35,07% |
Biaya operasional | 7,06 jt | -52,66% |
Laba bersih | -7,60 jt | 51,09% |
Margin laba bersih | -564,02 | 63,79% |
Penghasilan per saham | -1,88 | 53,00% |
EBITDA | -11,44 jt | 74,93% |
Tarif pajak efektif | 0,67% | — |
Neraca
Total aset
Total liabilitas
| (USD) | Jun 2025info | Perubahan Y/Y |
|---|---|---|
Investasi tunai jangka pdk | 23,37 jt | -83,39% |
Total aset | 178,06 jt | -39,27% |
Total liabilitas | 359,08 jt | -25,74% |
Total ekuitas | -181,03 jt | — |
Saham yang beredar | 4,04 jt | — |
Harga terhadap nilai buku | -0,20 | — |
Tingkat pengembalian aset | -16,98% | — |
Tingkat pengembalian modal | 33,97% | — |
Arus Kas
Perubahan kas bersih
| (USD) | Jun 2025info | Perubahan Y/Y |
|---|---|---|
Laba bersih | -7,60 jt | 51,09% |
Kas dari operasi | 12,68 jt | 131,81% |
Kas dari investasi | -13,00 rb | -100,02% |
Kas dari pembiayaan | -9,00 rb | -128,12% |
Perubahan kas bersih | 13,64 jt | -61,00% |
Arus kas bebas | -23,60 jt | 48,73% |
Tentang
FibroGen, Inc. is a biopharmaceutical company headquartered in San Francisco, California. Once regarded as a promising developer of innovative anemia and fibrosis therapies, the company’s reputation and market value declined sharply after 2020 following a series of late-stage trial failures, regulatory setbacks, and a data manipulation scandal involving its former chief medical officer. Wikipedia
Didirikan
1 Jan 1993
Kantor pusat
Situs
Karyawan
225
